Home >> News >> Alzheimer’s therapy flops in phase III clinical trial

Alzheimer’s therapy flops in phase III clinical trial

12-23-2014 16:37

News comes from: http://news.sciencemag.org/sifter/2014/12/alzheimer-s-therapy-flops-in-phase-iii-clinical-trial

On Dec. 19, 2014 Swiss pharmaceutical giant Roche announced it is ending a phase III clinical trial for the experimental drug gantenerumab, a monoclonal antibody therapy, because the drug has failed to actually help prevent Alzheimer’s disease, Bloomberg reports. Alzheimer’s is thought to be caused, at least in part, by the buildup of β-amyloid plaques in the brain. Gantenerumab was designed to be administered early in the disease’s progression, before severe symptoms develop. Despite promising early results, the antibodies did not halt the formation of the plaques in any meaningful way, sparking new debate over how to treat the debilitating neurological disorder and whether the plaques are even its primary cause.

Wellcome Images/Flickr (CC BY-NC-ND 2.0)



Copyright © 2013 International Union of Science & Education All rights reserved.